Restorative heart valves
Valve cardiaque restauratrice
A Revolution in Cardiovascular Treatment:
Xeltis is a clinical-stage European medical device company leveraging breakthrough science to transform heart valve therapy. Xeltis is revolutionizing the treatment of heart valve disease. The company’s restorative heart valves enable the patient’s own body to naturally form a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR). With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.
Xeltis has been granted permission by the US Food and Drug Association to begin its Xplore-II clinical trial for its pulmonary valve in the United States.
The company Xeltis AG was founded June 2006 and is based in Zurich, Switzerland.
Thank you for reading
Asia, Japan – business development – 営業開発・EU ・スイス ・Switzerland